Answers are grounded in this paper and cite their sources.
Avian reovirus (ARV) is an important poultry pathogen characterized by substantial genetic variability, which may compromise the effectiveness of vaccines based on classical strains. This study evaluated recombinant σC antigens produced in bacterial and plant-based expression systems as adaptable vaccine candidates against ARV. Seven Chilean field isolates collected over a five-year period were characterized through S1 sequencing and phylogenetic analysis. Most isolates clustered within genotype V, whereas one belonged to genotype I. Isolate 13726, which showed the greatest divergence among genotype V isolates and approximately 49% amino acid identity with the classical S1133 vaccine strain, was selected for recombinant antigen production. The σC protein was successfully expressed in Escherichia coli and transiently in Nicotiana benthamiana using a Tobacco mosaic virus-derived pTRBO vector, yielding recombinant proteins of approximately 35 kDa. Purified antigens were formulated with Montanide ISA 760 VG and administered to specific-pathogen-free chickens using a prime-boost vaccination schedule. Both recombinant formulations induced significant anti-σC antibody responses, which increased following booster immunization. Virus neutralization assays against homologous ARV isolate 13726 showed an approximately two-log reduction in infectivity. The pooled serum from chickens immunized with the N. benthamiana-derived formulation produced a neutralization index (NI) of 2.005, whereas pooled sera from the E. coli-derived formulation and the commercial Reomune® 3 vaccine produced NI values of 1.996 and 2.006, respectively. Because neutralization was assessed using pooled sera, these values were interpreted descriptively and were not subjected to statistical comparison among treatments.
No takes yet. Share an insight, caveat, or question.
Guzmán et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: